PDE4

Class

Phosphodiesterase-4 inhibitor

Phosphodiesterase-4 (PDE4) is an enzyme that breaks down cyclic adenosine monophosphate (cAMP), a small signaling molecule inside cells that dampens inflammatory activity when its levels are high. PDE4 is expressed abundantly in immune cells such as monocytes, macrophages, and T cells, as well as in epithelial and skin cells, where it keeps cAMP levels in check. Inhibiting PDE4 prevents the breakdown of cAMP, allowing it to accumulate and reduce the production of pro-inflammatory mediators such as tumor necrosis factor and various interleukins. This rationale makes PDE4 inhibition broadly relevant to chronic inflammatory diseases, including inflammatory skin conditions like psoriasis and atopic dermatitis, inflammatory bowel conditions, and airway diseases such as chronic obstructive pulmonary disease, where excessive inflammatory signaling drives tissue damage and symptoms. Because PDE4 is expressed in many organ systems, inhibitors can be formulated for systemic use, applied topically to the skin, or engineered as prodrugs that release the active drug locally, such as within the colon, to concentrate the anti-inflammatory effect where disease is active while limiting exposure elsewhere in the body. This flexibility in delivery reflects an effort to preserve efficacy while managing the tolerability challenges associated with broader PDE4 inhibition.